# Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial

> **NCT01966679** · PHASE2 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 40 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** AZD7325
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01966679
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01966679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01966679, "Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01966679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*